Evidence map›Paper›PMID 37855295›Full record

ReviewCNS & neurological disorders drug targets2024

Phosphodiesterase 2 and Its Isoform A as Therapeutic Targets in the Central Nervous System Disorders.

Sanjay K Metkar, Yuqing Yan, Yue Lu, Jianming Lu, Xiongwei Zhu, Fu Du, Ying Xu

Abstract readReview
PubMed Publisher
In one paragraph

Review in CNS & neurological disorders drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Research progress on phosphodiesterase 4 inhibitors in central nervous system diseases.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sanjay K MetkarDepartment of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103, USA.
Yuqing YanDepartment of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103, USA.
Yue LuDepartment of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103, USA.
Jianming LuCodex BioSolutions Inc. 12358 Parklawn Drive, Suite 250A, Rockville, MD 20852, Maryland.
Xiongwei ZhuDepartment of Pathology, Case Western Reserve University, Cleveland, Ohio 44106; USA.
Fu DuFD NeuroTechnologies Consulting & Services, Inc., Columbia, MD 21046, Maryland.
Ying XuDepartment of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ 07103, USA.
Rutgers, The State University of New Jersey · USCase Western Reserve University · USCodex Biosolutions (United States) · US

Funding

Role of PDE2A in mitochondrial dysfunction in Alzheimer’s diseaseR01AG070873 · NIA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI XU, YING, ZHU, XIONGWEI · 2021 to 2025
$3.8M
DEVELOPMENT OF NOVEL PDE4B INHIBITORS TO TREAT ALCOHOL USE DISORDER (SBIR PHASE II)75N94019C00010 · NICHD · CODEX BIOSOLUTIONS, INC. · PI LU, JIMMY · 2019 to 2019
$999k
Discovery of PDE2A inhibitors to treat memory deficits in mild cognitive impairment and Alzheimer's diseaseR43AG071045 · NIA · FD NEUROTECHNOLOGIES CONSULTING & SERVICES, INC. · PI DU, FU, O'DONNELL, JAMES M · 2021 to 2021
$500k
National Institute of Aging R01 AG070873-01A1, 2021-2026NICHD NIH HHS 75N94019C00010Small Business Innovation Research (SBIR) Program Phase I R43 AG071045-01A1, 2021-2023
6 · The paper itself

Abstract

Cyclic adenosine monophosphates (cAMP) and cyclic guanosine monophosphate (cGMP) are two essential second messengers, which are hydrolyzed by phosphodiesterase's (PDEs), such as PDE-2. Pharmacological inhibition of PDE-2 (PDE2A) in the central nervous system improves cAMP and cGMP signaling, which controls downstream proteins related to neuropsychiatric, neurodegenerative, and neurodevelopmental disorders. Considering that there are no specific treatments for these disorders, PDE-2 inhibitors' development has gained more attention in the recent decade. There is high demand for developing new-generation drugs targeting PDE2 for treating diseases in the central nervous and peripheral systems. This review summarizes the relationship between PDE-2 with neuropsychiatric, neurodegenerative, and neurodevelopmental disorders as well as its possible treatment, mainly involving inhibitors of PDE2.

Indexed as

Central Nervous System DiseasesCyclic Nucleotide Phosphodiesterases, Type 2Phosphodiesterase InhibitorsAnimalsCyclic AMPCyclic GMPHumansCyclic AMPCyclic GMPCyclic Nucleotide Phosphodiesterases, Type 2PDE2A protein, humanPhosphodiesterase Inhibitorscyclic AMP (cAMP)cyclic GMP (cGMP)neurodegenerativeneurodevelopmental disorders.neuropsychiatricPhosphodiesterase 2 (PDE2 or PDE2A)

Identifiers

PMID37855295
OpenAlexW4387655013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.